Navigation Links
Immunotherapy effective against neuroblastoma in children
Date:5/14/2009

the percentage of patients who were still alive without experiencing a recurrence after two years as well as overall survival in two groups of 113 patients each. Patients began the trial when they were newly diagnosed with high-risk neuroblastoma. After conventional treatment with surgery, chemotherapy, stem cell rescue and radiotherapy, one group was given the standard treatment (retinoic acid) plus immunotherapy (the antibody plus immune-boosting substances), while 113 similar patients received the standard treatment alone.

After two years, 66 percent of individuals in the immunotherapy group were living free of cancer compared to 46 percent in the standard treatment group. Overall survival improved significantly as well. The trial patient randomization was halted early because of the benefit seen, and all patients enrolled in the trial will receive immunotherapy plus standard treatment.

Yu noted that the two-year mark is especially important because past trials have shown that those neuroblastoma patients who live without disease for two years after a stem cell transplant will most likely be cured.

"This is the first time in many years that we have been able to improve the 'cure rate' for neuroblastoma patients," she said. "This new therapy can help us improve care and perhaps offer new hope to many patients and families."

Yu and her team conducted the early phase I and phase II trials at the General Clinical Research Center at UC San Diego Medical Center.


'/>"/>

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Sublingual immunotherapy for inhalant allergies deserves deeper consideration
2. Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
3. Device aims to decrease wait period for patients needing immunotherapy
4. A new light on tumor immunotherapy for gastric cancer
5. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
6. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
7. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
8. Towards improved immunotherapy
9. Educational Symposium to Present Panel Discussion on Melanoma Treatments and Immunotherapy
10. OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
11. Latest research on allergies: Specific immunotherapy can help
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... THURSDAY, Sept. 18, 2014 (HealthDay News) -- Daily supplements ... protect against the development of age-related cataracts among men, ... suggested that one or both could help prevent cataracts. ... Women,s Hospital and Harvard Medical School in Boston, and ... of selenium and vitamin E. The trial was initially ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... the Ebola virus invoke scary scenarios of deadly epidemics, ... are still providing researchers with new insights on how ... published online Sept. 18, 2014, in the journal ... Medical School Singapore detail how the Yersinia pestis bacteria ... the lymph nodes and eventually ride into the lungs ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2
... , PASO ROBLES, Calif., July 28 ... California, will make silicone micro-implants such as surgical drains, catheter ... not routine is the incredibly precise tolerances demanded of these ... achieving consistently precise results to within .001 inch is no ...
... , MAITLAND, Fla. , July 28 ... treatment for infants with plagiocephaly and other head shape abnormalities, opened ... The Center currently also has offices in the Baltimore and Dallas ... orthoses, also commonly referred to as a cranial helmets or headbands. ...
... HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ -- China ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... China ("PRC"), today announced that the,Company is scheduled to ... in early August, 2009. , ...
... , VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... "Company") today announced encouraging interim data from an ongoing ... the punctal plug delivery system. These studies are part ... QLT,s wholly-owned subsidiary, QLT Plug Delivery, Inc. , Preliminary ...
... , , THE WOODLANDS, Texas, ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... financial results for the three months and six months ended June 30, ... progress, including the recent initiation of a Phase 2 study of LX1032 ...
... MINNEAPOLIS, July 28 ATS Medical, Inc. (Nasdaq: ATSI ... that it will participate in two upcoming investor conferences. ... The Company will participate in the 9th Annual BMO ... in New York. Michael Kramer, CFO of ATS Medical, will ...
Cached Medicine News:Health News:When You Make Things That Get Implanted in People, Small Things Count 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5Health News:China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 3Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 4Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 5Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 6Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 2Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 3Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 4Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 5Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 6Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 8Health News:ATS Medical to Participate at Upcoming Investor Conferences 2
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... 18, 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), ... of chronic pain, announced today that it has appointed ... of  Senior Director of Clinical Development. During ... established and led successful global clinical operations teams, in ... facilitate the clinical development of numerous therapeutics and diagnostics ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
B-52 Wrap Frame...
Medicine Products: